| Literature DB >> 35356648 |
Yu Yang1, Yang Xiaohui1, Sui Miao1, Zhong Yingshuo1.
Abstract
Background: In this study, we performed a bidirectional mendelian randomization analysis on circulating cytokines and critically ill COVID-19.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35356648 PMCID: PMC8934535 DOI: 10.7189/jogh.12.05010
Source DB: PubMed Journal: J Glob Health ISSN: 2047-2978 Impact factor: 4.413
MR analysis results of 24 cytokines to critically ill COVID-19 direction*
| Cytokines | Number of SNPs | Variance explained | F statistics | Beta | SE | ||
|---|---|---|---|---|---|---|---|
| CTACK | 2 | 0.049 | 184.615 | 0.055 | 0.086 | 0.526 | 0.789 |
| bNGF | 1 | 0.011 | 39.017 | 0.016 | 0.229 | 0.946 | 0.946 |
| VEGF | 7 | 0.045 | 320.340 | -0.094 | 0.057 | 0.103 | 0.786 |
| TRAIL | 12 | 0.245 | 2074.603 | -0.071 | 0.044 | 0.106 | 0.786 |
| TNFb | 2 | 0.104 | 173.738 | 0.066 | 0.090 | 0.462 | 0.786 |
| SCGFb | 3 | 0.071 | 266.890 | 0.095 | 0.091 | 0.296 | 0.786 |
| SCF | 2 | 0.010 | 87.294 | -0.443 | 0.311 | 0.155 | 0.786 |
| IL16 | 3 | 0.092 | 342.450 | -0.005 | 0.063 | 0.936 | 0.946 |
| RANTES | 1 | 0.004 | 13.974 | 0.249 | 0.342 | 0.467 | 0.786 |
| PDGFbb | 6 | 0.070 | 592.388 | -0.080 | 0.076 | 0.291 | 0.786 |
| MIP1b | 18 | 0.305 | 2630.814 | 0.062 | 0.066 | 0.344 | 0.786 |
| MIG | 1 | 0.010 | 38.195 | -0.016 | 0.236 | 0.945 | 0.946 |
| MCSF | 1 | 0.016 | 13.724 | -0.220 | 0.200 | 0.271 | 0.786 |
| MCP1 | 2 | 0.024 | 203.860 | -0.167 | 0.216 | 0.440 | 0.786 |
| IL12p70 | 4 | 0.018 | 149.053 | 0.097 | 0.195 | 0.617 | 0.824 |
| IP10 | 2 | 0.019 | 71.290 | -0.286 | 0.234 | 0.221 | 0.786 |
| IL18 | 3 | 0.041 | 150.175 | 0.015 | 0.125 | 0.905 | 0.946 |
| IL17 | 1 | 0.005 | 41.923 | -0.152 | 0.337 | 0.652 | 0.824 |
| IL13 | 1 | 0.089 | 347.870 | -0.099 | 0.089 | 0.265 | 0.786 |
| IL10 | 1 | 0.005 | 37.121 | -0.300 | 0.345 | 0.384 | 0.786 |
| HGF | 2 | 0.015 | 128.368 | 0.067 | 0.143 | 0.636 | 0.824 |
| IL5† | 1 | 0.011 | 38.656 | -0.395 | 0.182 | 0.030 | 0.720 |
| GROa | 2 | 0.119 | 444.370 | -0.004 | 0.054 | 0.934 | 0.946 |
| Eotaxin | 2 | 0.027 | 222.288 | -0.066 | 0.096 | 0.491 | 0.786 |
SE – standard error, Padjust – FDR (false discovery rate) corrected P value
*Explained variance was calculated as: R2 = (reported GWAS effect)2 × 2 × minor allele frequency × (1 – minor allele frequency) / variance of trait. F statistics per variant was calculated as: (Sample size - 2) × R2 / (1 – R2). The Wald ratio estimator was used for effect estimation if one single instrument was available, and the inverse variance weighted estimation method (IVW) when more than one instrument was available.
†P value of IL5 showed suggestive significance at the level of 0.05.
MR analysis results of critically ill COVID-19 to 41 cytokines direction
| Cytokines | Number of SNPs* | Beta | SE | ||
|---|---|---|---|---|---|
| CTACK | 8 | 0.042 | 0.062 | 0.494 | 0.856 |
| bNGF† | 7 | -0.093 | 0.046 | 0.044 | 0.574 |
| VEGF | 7 | -0.048 | 0.033 | 0.145 | 0.688 |
| MIF | 7 | -0.023 | 0.047 | 0.628 | 0.888 |
| TRAIL | 8 | -0.010 | 0.034 | 0.766 | 0.894 |
| TNFb | 7 | -0.047 | 0.087 | 0.590 | 0.888 |
| TNFa | 8 | -0.018 | 0.057 | 0.755 | 0.894 |
| SDF1a | 8 | -0.008 | 0.031 | 0.788 | 0.894 |
| SCGFb | 7 | -0.060 | 0.059 | 0.306 | 0.856 |
| SCF | 7 | -0.036 | 0.030 | 0.240 | 0.856 |
| IL16 | 8 | 0.014 | 0.045 | 0.766 | 0.894 |
| RANTES | 8 | 0.006 | 0.072 | 0.939 | 0.939 |
| PDGFbb | 7 | 0.015 | 0.030 | 0.628 | 0.888 |
| MIP1b | 8 | -0.026 | 0.041 | 0.520 | 0.856 |
| MIP1a | 7 | -0.040 | 0.046 | 0.390 | 0.856 |
| MIG | 7 | -0.017 | 0.059 | 0.777 | 0.894 |
| MCSF | 7 | -0.087 | 0.055 | 0.116 | 0.688 |
| MCP3 | 8 | -0.126 | 0.088 | 0.151 | 0.688 |
| MCP1 | 7 | -0.033 | 0.030 | 0.278 | 0.856 |
| IL12p70 | 6 | -0.029 | 0.034 | 0.393 | 0.856 |
| IP10 | 6 | 0.038 | 0.069 | 0.575 | 0.888 |
| IL18 | 7 | 0.015 | 0.046 | 0.749 | 0.894 |
| IL17 | 8 | -0.037 | 0.031 | 0.225 | 0.856 |
| IL13 | 7 | -0.047 | 0.046 | 0.311 | 0.856 |
| IL10 | 7 | -0.060 | 0.031 | 0.056 | 0.574 |
| IL8‡ | 7 | -0.091 | 0.046 | 0.049 | 0.574 |
| IL6 | 7 | -0.007 | 0.031 | 0.807 | 0.894 |
| IL1ra | 7 | -0.016 | 0.046 | 0.730 | 0.894 |
| IL1b | 7 | -0.058 | 0.036 | 0.113 | 0.688 |
| HGF | 7 | -0.058 | 0.030 | 0.055 | 0.574 |
| IL9 | 8 | -0.004 | 0.045 | 0.920 | 0.939 |
| IL7 | 7 | -0.036 | 0.047 | 0.445 | 0.856 |
| IL5 | 7 | -0.073 | 0.047 | 0.121 | 0.688 |
| IL4 | 7 | -0.026 | 0.031 | 0.395 | 0.856 |
| IL2ra | 7 | -0.036 | 0.057 | 0.522 | 0.856 |
| IL2 | 7 | -0.039 | 0.047 | 0.406 | 0.856 |
| IFNg | 7 | 0.004 | 0.032 | 0.894 | 0.939 |
| GROa | 7 | -0.075 | 0.078 | 0.334 | 0.856 |
| GCSF | 8 | -0.003 | 0.030 | 0.910 | 0.939 |
| FGFbasic | 8 | -0.023 | 0.031 | 0.452 | 0.856 |
| Eotaxin | 7 | -0.020 | 0.031 | 0.522 | 0.856 |
SNP – single nucleotide polymorphism, SE – standard error, Padjust – FDR (false discovery rate) corrected P value
*The inverse variance weighted estimation method (IVW) was used in this direction, for six to eight SNPs were available.
†P value of bNGF showed suggestive significance at the level of 0.05.
‡P value of IL8 showed suggestive significance at the level of 0.05.
Heterogeneity and pleiotropy tests for bNGF and IL8 IVs in the critically ill COVID-19 to cytokines direction
| Heterogeneity test | Pleiotropy test | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| bNGF | MR-Egger | 2.576 | 1.000 | 0.765 | -0.002 | 0.043 | 0.962 |
| IVW | 2.578 | 1.388 | 0.860 |
|
|
| |
| IL8 | MR-Egger | 1.051 | 1.952 | 0.958 | -0.005 | 0.043 | 0.904 |
| IVW | 1.067 | 1.938 | 0.983 | ||||
SE – standard error
Validation study of MR results in another COVID-19 data set
| Exposures | Outcomes | Beta | SE | OR | 95% CI | ||
|---|---|---|---|---|---|---|---|
| IL5 | Critically ill COVID-19 | -0.437 | 0.187 | 0.019* | 0.646 | 0.448, 0.932 | 0.456 |
| Critically ill COVID-19 | bNGF | -0.088 | 0.050 | 0.080 |
|
|
|
| Critically ill COVID-19 | IL8 | -0.087 | 0.050 | 0.081 |
MR – Mendelian randomization, OR – odds ratio, CI – confidence interval
*P value of IL5 showed suggestive significance at the level of 0.05 in the cytokine to critically ill COVID-19 direction.